Evidence supporting the use of: Green chiretta
For the health condition: Malaria

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Green chiretta (Andrographis paniculata) has a long history of use in traditional medicine, particularly in Asia, for the treatment of various infectious diseases, including malaria. Scientifically, several laboratory and animal studies have reported that extracts of Andrographis paniculata and its main active compound, andrographolide, exhibit antimalarial activity. For example, in vitro studies have shown inhibition of Plasmodium falciparum growth, and some animal models have demonstrated reduced parasitemia and improved survival in malaria-infected mice treated with extracts of the plant. The proposed mechanisms of action include interference with the parasite’s life cycle and immunomodulatory effects that may enhance the host’s ability to combat infection.

Despite these promising findings, high-quality human clinical trials are limited. Some small-scale studies and ethnobotanical surveys suggest potential benefits, but the evidence is not robust enough to recommend green chiretta as a primary treatment for malaria over established antimalarial drugs. The World Health Organization does not endorse its use as a standard malaria therapy. In summary, there is scientific evidence supporting its antimalarial effects in preclinical settings, but clinical validation remains insufficient. Thus, while green chiretta is supported by both tradition and early scientific research, its role in malaria treatment should be considered complementary and experimental, not a replacement for proven medical therapies.

More about green chiretta
More about Malaria